South Delhi Pharma, New Delhi, India
Zejula (niraparib) capsules, for oral use
Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email firstname.lastname@example.org to discuss.
Facts of Zejula (niraparib) capsules
Product: ZEJULA (niraparib) capsules, for oral use
Initial U.S. Approval: 2017
Capsules: 100 mg
Indication: epithelial ovarian, fallopian tube, or primary peritoneal cancer
South Delhi Pharma can facilitate patients and physicians access to commercially approved medicines, “Zejula (niraparib)” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Zejula (niraparib) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
M:+91-9891296838 / P:+91-11- 26532129
What Zejula is?
ZEJULA is a poly(ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy
What niraparib is?
The drug is approved by the US FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib (trade name Zejula) is an orally active small molecule PARP inhibitor developed by Tesaro to treat ovarian cancer. Niraparib was granted fast track designation by the US Food and Drug Administration (FDA), and Tesaro submitted a new drug application in 2016. It was approved on 27 March 2017 in the US, and has been approved in Europe on 16 November 2017.